Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 433

1.

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.

Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, Janssen JJWM, Mahon FX, Minami Y, Yeung D, Ross DM, Tallman MS, Park JH, Druker BJ, Hynds D, Duan Y, Meille C, Hourcade-Potelleret F, Vanasse KG, Lang F, Kim DW.

N Engl J Med. 2019 Dec 12;381(24):2315-2326. doi: 10.1056/NEJMoa1902328.

PMID:
31826340
2.

Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia.

Braun TP, Okhovat M, Coblentz C, Carratt SA, Foley A, Schonrock Z, Smith BM, Nevonen K, Davis B, Garcia B, LaTocha D, Weeder BR, Grzadkowski MR, Estabrook JC, Manning HG, Watanabe-Smith K, Jeng S, Smith JL, Leonti AR, Ries RE, McWeeney S, Di Genua C, Drissen R, Nerlov C, Meshinchi S, Carbone L, Druker BJ, Maxson JE.

Nat Commun. 2019 Nov 29;10(1):5455. doi: 10.1038/s41467-019-13364-2.

3.

Differentiation of leukemic blasts is not completely blocked in acute myeloid leukemia.

Agarwal A, Bolosky WJ, Wilson DB, Eide CA, Olson SB, Fan G, Druker BJ.

Proc Natl Acad Sci U S A. 2019 Dec 3;116(49):24593-24599. doi: 10.1073/pnas.1904091116. Epub 2019 Nov 21.

PMID:
31754026
4.

Replication timing alterations in leukemia affect clinically relevant chromosome domains.

Rivera-Mulia JC, Sasaki T, Trevilla-Garcia C, Nakamichi N, Knapp DJHF, Hammond CA, Chang BH, Tyner JW, Devidas M, Zimmerman J, Klein KN, Somasundaram V, Druker BJ, Gruber TA, Koren A, Eaves CJ, Gilbert DM.

Blood Adv. 2019 Nov 12;3(21):3201-3213. doi: 10.1182/bloodadvances.2019000641.

5.

Revisiting NTRKs as an emerging oncogene in hematological malignancies.

Joshi SK, Davare MA, Druker BJ, Tognon CE.

Leukemia. 2019 Nov;33(11):2563-2574. doi: 10.1038/s41375-019-0576-8. Epub 2019 Sep 24. Review.

PMID:
31551508
6.

Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.

Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, Schultz AR, Clair P, Bowler AD, Pomicter AD, Yan D, Senina AV, Qiang W, Kelley TW, Szankasi P, Heinrich MC, Tyner JW, Rea D, Cayuela JM, Kim DW, Tognon CE, O'Hare T, Druker BJ, Deininger MW.

Cancer Cell. 2019 Oct 14;36(4):431-443.e5. doi: 10.1016/j.ccell.2019.08.004. Epub 2019 Sep 19.

7.

Genomic landscape of neutrophilic leukemias of ambiguous diagnosis.

Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister Schultz A, Long N, White L, Carlos A, Henson R, Lin C, Searles R, Collins RH, DeAngelo DJ, Deininger MW, Dunn T, Hein T, Luskin MR, Medeiros BC, Oh ST, Pollyea DA, Steensma DP, Stone RM, Druker BJ, McWeeney SK, Maxson JE, Gotlib JR, Tyner JW.

Blood. 2019 Sep 12;134(11):867-879. doi: 10.1182/blood.2019000611. Epub 2019 Jul 31.

PMID:
31366621
8.

Challenges and approaches to implementing master/basket trials in oncology.

Burd A, Schilsky RL, Byrd JC, Levine RL, Papadimitrakopoulou VA, Herbst RS, Redman MW, Druker BJ, Gandara DR.

Blood Adv. 2019 Jul 23;3(14):2237-2243. doi: 10.1182/bloodadvances.2019031229.

9.

Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation.

Burslem GM, Schultz AR, Bondeson DP, Eide CA, Savage Stevens SL, Druker BJ, Crews CM.

Cancer Res. 2019 Sep 15;79(18):4744-4753. doi: 10.1158/0008-5472.CAN-19-1236. Epub 2019 Jul 16.

PMID:
31311809
10.

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.

Branford S, Kim DDH, Apperley JF, Eide CA, Mustjoki S, Ong ST, Nteliopoulos G, Ernst T, Chuah C, Gambacorti-Passerini C, Mauro MJ, Druker BJ, Kim DW, Mahon FX, Cortes J, Radich JP, Hochhaus A, Hughes TP; International CML Foundation Genomics Alliance.

Leukemia. 2019 Aug;33(8):1835-1850. doi: 10.1038/s41375-019-0512-y. Epub 2019 Jun 17. Review.

11.

The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML.

Dunlap JB, Leonard J, Rosenberg M, Cook R, Press R, Fan G, Raess PW, Druker BJ, Traer E.

Am J Hematol. 2019 Aug;94(8):913-920. doi: 10.1002/ajh.25517. Epub 2019 Jun 21.

12.

The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.

Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D'Alessandro A, Culp-Hill R, d'Almeida A, Joshi SK, Rosenberg M, Tognon CE, Danilov AV, Druker BJ, Chang BH, McWeeney SK, Tyner JW.

Cancer Discov. 2019 Jul;9(7):910-925. doi: 10.1158/2159-8290.CD-19-0125. Epub 2019 May 2.

PMID:
31048320
13.

Correction: FGF2-FGFR1 signaling regulates release of leukemia-protective exosomes from bone marrow stromal cells.

Javidi-Sharifi N, Martinez J, English I, Joshi SK, Scopim-Ribeiro R, Viola SK, Edwards DK 5th, Agarwal A, Lopez C, Jorgens D, Tyner JW, Druker BJ, Traer E.

Elife. 2019 Mar 29;8. pii: e47174. doi: 10.7554/eLife.47174.

14.

FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells.

Javidi-Sharifi N, Martinez J, English I, Joshi SK, Scopim-Ribeiro R, Viola SK, Edwards DK 5th, Agarwal A, Lopez C, Jorgens D, Tyner JW, Druker BJ, Traer E.

Elife. 2019 Feb 5;8. pii: e40033. doi: 10.7554/eLife.40033. Erratum in: Elife. 2019 Mar 29;8:.

15.

Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib.

Latifi Y, Moccetti F, Wu M, Xie A, Packwood W, Qi Y, Ozawa K, Shentu W, Brown E, Shirai T, McCarty OJ, Ruggeri Z, Moslehi J, Chen J, Druker BJ, López JA, Lindner JR.

Blood. 2019 Apr 4;133(14):1597-1606. doi: 10.1182/blood-2018-10-881557. Epub 2019 Jan 28.

PMID:
30692122
16.

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.

Zhang H, Savage S, Schultz AR, Bottomly D, White L, Segerdell E, Wilmot B, McWeeney SK, Eide CA, Nechiporuk T, Carlos A, Henson R, Lin C, Searles R, Ho H, Lam YL, Sweat R, Follit C, Jain V, Lind E, Borthakur G, Garcia-Manero G, Ravandi F, Kantarjian HM, Cortes J, Collins R, Buelow DR, Baker SD, Druker BJ, Tyner JW.

Nat Commun. 2019 Jan 16;10(1):244. doi: 10.1038/s41467-018-08263-x.

17.

Predicting response to BET inhibitors using computational modeling: A BEAT AML project study.

Drusbosky LM, Vidva R, Gera S, Lakshminarayana AV, Shyamasundar VP, Agrawal AK, Talawdekar A, Abbasi T, Vali S, Tognon CE, Kurtz SE, Tyner JW, McWeeney SK, Druker BJ, Cogle CR.

Leuk Res. 2019 Feb;77:42-50. doi: 10.1016/j.leukres.2018.11.010. Epub 2019 Jan 7.

18.

Reply to N. Cerveira et al.

Berman E, Druker BJ, Burwick R.

J Clin Oncol. 2019 Jan 1;37(1):90-91. doi: 10.1200/JCO.18.01004. Epub 2018 Nov 13. No abstract available.

PMID:
30422739
19.

Functional genomic landscape of acute myeloid leukaemia.

Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DK 5th, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, Deininger MW, Drusbosky L, Hourigan CS, Jordan CT, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, Pollyea DA, Swords RT, Watts JM, Weir SJ, Wiest DL, Winters RM, McWeeney SK, Druker BJ.

Nature. 2018 Oct;562(7728):526-531. doi: 10.1038/s41586-018-0623-z. Epub 2018 Oct 17.

20.

Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.

Davare MA, Henderson JJ, Agarwal A, Wagner JP, Iyer SR, Shah N, Woltjer R, Somwar R, Gilheeney SW, DeCarvalo A, Mikkelson T, Van Meir EG, Ladanyi M, Druker BJ.

Clin Cancer Res. 2018 Dec 15;24(24):6471-6482. doi: 10.1158/1078-0432.CCR-18-1052. Epub 2018 Aug 31.

PMID:
30171048

Supplemental Content

Loading ...
Support Center